Direkt zum Inhalt
Merck

SML2956

Sigma-Aldrich

Nalmefene Hydrochloride

≥98% (HPLC)

Synonym(e):

(5a)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylene-morphinan-3,14-diol hydrochloride, NIH 1036, Nalmefene HCl

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C21H25NO3·HCl
CAS-Nummer:
Molekulargewicht:
375.89
MDL-Nummer:
UNSPSC-Code:
12352200
NACRES:
NA.77

Qualitätsniveau

Assay

≥98% (HPLC)

Form

powder

Lagerbedingungen

desiccated

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL, clear

Lagertemp.

2-8°C

SMILES String

C=C1CC[C@@]2(O)[C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]1OC5=C(C=C4)O.Cl

InChI

1S/C21H25NO3.ClH/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13;/h4-5,13,16,19,23-24H,1-3,6-11H2;1H/t16-,19+,20+,21-;/m1./s1

InChIKey

GYWMRGWFQPSQLK-OPHZJPRHSA-N

Biochem./physiol. Wirkung

Nalmefene hydrochloride, a naltrexone analogue, is an inverse agonist at the μ-opioid receptor (MOR) and as a weak partial agonist at the κ-opioid receptor. Nalmefene hydrochloride is used as treatment for addiction.

Piktogramme

Skull and crossbonesEnvironment

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Oral - Aquatic Chronic 1 - STOT SE 3

Zielorgane

Central nervous system

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Bernadett I Gál et al.
Frontiers in pharmacology, 10, 1087-1087 (2019-10-16)
Nalmefene is approved for as-needed pharmacological treatment in alcohol use disorder (AUD) by the European Medicines Agency. While the cellular effects of nalmefene have been thoroughly investigated, data are very limited on how this agent influences neural signals associated with
Karl Mann et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 26(12), 1941-1949 (2016-11-16)
Nalmefene, a mu- and delta-opioid receptor (MOR, DOR) antagonist and a partial kappa-opioid receptor (KOR) agonist, is approved in the European Union and other countries for the reduction of alcohol consumption in alcohol dependent patients with a high drinking risk
Javier Calleja-Conde et al.
British journal of pharmacology, 173(16), 2490-2505 (2016-05-31)
The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European Medicines Agency in 2013. However, there have been no studies regarding the effectiveness of nalmefene when alcohol is used in combination with cocaine. Using operant alcohol self-administration

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.